Obesity in children with acute promyelocytic leukemia: What is its prevalence and prognostic significance?
Kathryn L Laurie, Paul Lee, Alfred Rademaker, Todd A Alonzo, Yi-Cheng Wang, Bayard L Powell, Diana Wu, Richard Larson, Matthew Kutny, John Gregory and 2 more
Review in Pediatric blood & cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 11 institutions in 1 country.
Kathryn L LaurieDepartment of Pediatric Hematology/Oncology, Goryeb Children's Hospital of Morristown Medical Center, Morristown, New Jersey, USA.ORCID 0000-0001-7726-3309
Paul LeeAbbVie, Chicago, Illinois, USA.
Alfred RademakerDepartment of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Todd A AlonzoDepartment of Preventive Medicine, University of Southern California, Los Angeles, California, USA.
Yi-Cheng WangDepartment of Biostatistics, University of Southern California, Los Angeles, California, USA.
Bayard L PowellWake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, USA.
Diana WuSt. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Richard LarsonUniversity of Chicago, Chicago, Illinois, USA.
Matthew KutnyDepartment of Pediatrics, Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0002-6659-7036
John GregoryNovartis, East Hanover, New Jersey, USA.
Nobuko HijiyaDivision of Hematology/Oncology/Stem Cell Transplant, Columbia University Medical Center, New York, New York, USA.ORCID 0000-0002-0199-054X
James FeusnerDivision of Pediatric Hematology Oncology, Children's Hospital & Research Center Oakland, Benioff Children's Hospital Oakland, Oakland, California, USA.
University of Southern California · USAbbVie (United States) · USAtrium Health Wake Forest Baptist · USColumbia University Irving Medical Center · USMorristown Medical Center · USNorthwestern University · USNovartis (United States) · USSt. Jude Children's Research Hospital · USUCSF Benioff Children's Hospital · USUniversity of Alabama at Birmingham · USUniversity of Chicago · US
Funding
NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Statistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0M
Columbia University NCI Community Oncology Research ProgramUG1CA189960 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Jennifer E. Amengual, Lisa A. Kachnic · 2014 to 2026
$12.7M
Northwestern University Lead Academic Participating Site Supplement Year 2UG1CA233320 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BENSON, AL B, MATEI, DANIELA E · 2019 to 2025
$5.5M
UG1 - NCTN (Network Lead)UG1CA233327 · NCI · UNIVERSITY OF CHICAGO · PI STEVEN J CHMURA, HEDY L KINDLER · 2019 to 2026
$4.4M
NCTN - Network Lead Academic Participating Site: USCUG1CA180830 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Anthony Boutros El-Khoueiry, Amir Goldkorn · 2019 to 2026
objectiveTo compare outcomes of obese and nonobese pediatric patients with acute promyelocytic leukemia (APL) from the Cancer and Leukemia Group B trial (CALGB) 9710 and the Children's Oncology Group trial AAML0631.
methodsData including demographics, adverse events, overall and event-free survival (EFS) were analyzed.
resultsThe prevalence of obesity was 34% on C9710 and 35% on AAML0631. There was significantly lower overall and EFS in the obese population on multivariable analysis on AAML0631 but not on CALGB 9710. Eleven patients died during therapy or in follow-up.
conclusionThe prevalence of obesity is higher in pediatric patients with APL compared to the general population. The decreased EFS and OS in obese patients on AAML0631 suggest that the presence of obesity can influence outcomes using the most current treatment. These findings support the need for further research on the potential role of obesity in pediatric APL leukemogenesis.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Obesity in children with acute promyelocytic leukemia: What is its prevalence and prognostic significance? · full record | OpenQuestion